Loading
Life sciences · Observational Study
ClinicalTrials.gov · September 18, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Observational Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05655650). This is a study registration, not published results. Lead sponsor: Chinese University of Hong Kong. Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 300 participants (ESTIMATED). Conditions: Neuro-Degenerative Disease, Alzheimer Disease. Primary outcome measures: The score change in Hong Kong List Learn Test (HKLLT) , Baseline, 1 year, 2 year, 3 year ,4 year ,5 year and 6 year visit after baseline visit; The score change in Montreal Cognitive Assessment Hong Kong (HK-MoCA) , Baseline, 1 year, 2 year, 3 year ,4 year ,5 year and 6 year visit after baseline visit; The score change Clinical Dementia Rating (CDR) , Baseline, 1 year, 2 year, 3 year ,4 year ,5 year and 6 year visit after baseline visit; Amount of amyloid β with 11C-Pittsburgh compound B , Baseline; Amount of amyloid tau with T807 tracer , Baseline; Amount of glucose hypometabolism , Baseline; arterial spin labeling magnetic resonance perfusion (ASL-MRP) , Baseline; Change of Automatic Retinal Imaging , Baseline, 6th year follow up. Brief summary: Alzheimer's disease is a severe neurodegenerative disorder of the brain that is characterized by progressive loss of memory and cognitive decline. With the ageing population, AD is a major public health problem affecting nearly 35 million people worldwide with numbers projected to rise to 115.4 million by 2050. AD is the only cause of death among the top ten causes that has no prevention or cure . It is believed that novel treatment of AD needs to start early or even at the prodromal stage in order to be effective. Therefore, there is an urgent need to find accurate methods of early detection before patients with AD develop clinical dementia. This study aims to identify biomarkers for AD in local Chinese population. this study hypothesizes blood-based proteomics, retinal imaging, ASL-MRP and tau PET can improve the accuracy and staging of AD.